Country Overviews: market research reports

... and pharmaceutical industry to reduce thefinancial burden of diseases, and the country's private healthcare sectors provide opportunities forforeign companies. However, the increasing drug rebate level has significantly undermined the profitsrecorded by generic drugmakers. The more ...  |  more...

... margins and introduced insecurityto an already difficult economic environment, and we continue to expect a contraction in the size of theHungarian pharmaceutical market in 2012 and 2013. Consequently, Hungarian drugmakers will have tobecome even more ...  |  more...

... Portugal has already made considerable savings in the healthcaresectors, with changes such as the introduction of e-prescriptions and prescribing by active ingredients,changes to reference pricing, reductions in pharmacy margins and price cuts just some of ...  |  more...

... are a small improvement, though definitely not what producerswould have wanted ideally. With part of the objective of the claw-back tax to improve the timeliness ofpayments for reimbursed medicines, which has been a major difficulty ...  |  more...

... the evidence ofbribery and corruption, and the shortage of doctors in the sector. BMI believes the commitment toimprove governance and implement controls in the sector will be fulfilled in the medium-to-long term. Assuch, we maintain ...  |  more...

... this is realised. We do not expect either of the two private insurers - Dôvera or DutchownedUnion - will surrender their businesses without a fight, with Union in particular well-placedto oppose the move, potentially invoking ...  |  more...

... believes the government needs to do more to alter patients' attitudestowards these drugs as this is the main growth deterrent. Headline Expenditure Projections Pharmaceuticals: CHF6.77bn (US$7.63bn) in 2011 to CHF6.58bn (US$7.00bn) in 2012; -2.8% declinein ...  |  more...

... non-oil economies. Political risk remains elevated as many disputesbetween them are still unresolved. These macroeconomic uncertainties will mean lack of focus on publichealthcare provision, which further complicates the problem that the general population are unable ...  |  more...

... and the vast majority of expenditure will be on low-marginessential medicines. Due to tepid economic growth, our outlook for Gabon's pharmaceutical market isbelow that expected to be posted by many of its sub-Saharan Africa neighbours. ...  |  more...

... from the EU. The implementation of a clawbacktax at the start of the year will increase pricing pressures. VAT rises and inflation suggest growth seen in2012 will not be due to increased drug consumption. We ...  |  more...

... comparison to regional peers such as Singapore, Taiwan,China and South Korea means that the attractiveness of the market will dwindle over the longer term,should other developing countries such as Indonesia, Malaysia and the Philippines succeed ...  |  more...

... theyear. BMI notes that this does not bode well for drugmakers selling their products in Italy as the successof the implemented policies may encourage the enforcement of further cost-containment measures,which, together with the ongoing public ...  |  more...